Roivant Sciences Ltd.ROIVNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 93% recommend buying.

Consensus Rating

Buy

14 analysts·Moderate coverage

93%

Rating Distribution

Strong Buy

00%

Buy

1393%

Hold

17%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see moderate upside — consensus target 21% higher.

Bear Case

$20.00

-9%

Consensus

$26.50

+21%

Bull Case

$32.00

+46%

Price Range14 analysts

Low

Consensus

High

$20.00

$32.00

Current Target

Current Price

$21.91

Upside to Target

$4.59

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.12(3 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+846.83%

EPS—

FY2028

Rev+444.74%

EPS—

FY2029

Rev+168.45%

EPS—

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+10.2%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 18, 2025Guggenheim

Roivant Sciences price target raised to $28 from $25 at Guggenheim

Target:$28.00

+25.6%from $22.30

Dec 15, 2025Leerink Partners

Roivant Sciences (ROIV) PT Raised to $32 at Leerink Partners

Target:$32.00

+44.8%from $22.09

Dec 12, 2025H.C. Wainwright

Roivant Sciences price target raised to $26 from $23 at H.C. Wainwright

Target:$26.00

+21.1%from $21.46

Nov 14, 2025Guggenheim

Roivant Sciences (ROIV) PT Raised to $25 at Guggenheim

Target:$25.00

+21.6%from $20.56

Nov 11, 2025Leerink Partners

Roivant Sciences (ROIV) PT Raised to $29 at Leerink Partners

Target:$29.00

+37.0%from $21.17

Sep 18, 2025Jefferies

Roivant Sciences price target raised to $20 from $18 at Jefferies

Target:$20.00

+29.3%from $15.47

Sep 18, 2025Guggenheim

Roivant Sciences price target raised to $21 from $15 at Guggenheim

Target:$21.00

+37.8%from $15.24

Sep 18, 2025H.C. Wainwright

Roivant Sciences price target raised to $20 from $18 at H.C. Wainwright

Target:$20.00

+31.2%from $15.24

Oct 21, 2024Leerink Partners

Leerink Partners Reiterates Outperform Rating on Roivant Sciences (ROIV)

Target:$17.00

+42.6%from $11.92

Sep 19, 2024Goldman Sachs

Goldman Sachs Reiterates Buy Rating on Roivant Sciences (ROIV)

Target:$17.00

+41.0%from $12.05

Sep 11, 2024Bank of America Securities

Roivant Sciences (ROIV) PT Raised to $12.50 at BofA Securities

Target:$12.50

+0.4%from $12.46

May 31, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Roivant Sciences (ROIV)

Target:$20.00

+92.5%from $10.39

Apr 3, 2024H.C. Wainwright

Roivant Sciences (ROIV) PT Raised to $18 at H.C. Wainwright, 'brepocitinib has blockbuster potential'

Target:$18.00

+64.8%from $10.92

Apr 3, 2024Deutsche Bank

Roivant Sciences price target raised to $15 from $14 at Deutsche Bank

Target:$15.00

+37.4%from $10.92

Apr 2, 2024Goldman Sachs

Roivant Sciences (ROIV) PT Raised to $18 at Goldman Sachs

Target:$18.00

+64.8%from $10.92

Mar 13, 2024Goldman Sachs

Roivant Sciences (ROIV) PT Raised to $16 at Goldman Sachs

Target:$16.00

+50.7%from $10.62

Jan 5, 2023Citigroup

Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $14

Target:$14.00

+85.2%from $7.56

Dec 19, 2022Leerink Partners

SVB Leerink Maintains Outperform on Roivant Sciences, Raises Price Target to $10

Target:$10.00

+36.6%from $7.32

Aug 18, 2022Citigroup

Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $10

Target:$10.00

+147.5%from $4.04

May 24, 2022Goldman Sachs

Goldman Sachs Maintains Buy on Roivant Sciences, Lowers Price Target to $12

Target:$12.00

+210.9%from $3.86

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance